戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 pproach to rapidly antagonize deep levels of neuromuscular block.
2 ule rebinds cation and regains catalytic and neuromuscular blocking activity.
3 ents (17.0%) in the control group received a neuromuscular blocking agent (median dose, 38 mg).
4 pertoire [10/44 (23%) lacked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39
5                   Eleven patients received a neuromuscular blocking agent (NMBA) without a sedative/a
6 who did not receive a continuous infusion of neuromuscular blocking agent 11%; p < 0.001 by weighted
7 tients who received a continuous infusion of neuromuscular blocking agent 21% vs patients who did not
8   Respiratory involvement was more common in neuromuscular blocking agent allergy, while urticaria/an
9 xamined the association between receipt of a neuromuscular blocking agent and in-hospital mortality a
10 tients who received a continuous infusion of neuromuscular blocking agent and patients who did not re
11                          Whether the type of neuromuscular blocking agent and the duration of use are
12 e-Dawley rats (age 4 months), treated with a neuromuscular blocking agent and ventilated: control, hy
13  an instrumental variable found receipt of a neuromuscular blocking agent associated with a 4.3% (95%
14 ncluding 1,818 (23%) who were treated with a neuromuscular blocking agent by hospital day 2.
15 tients who received a continuous infusion of neuromuscular blocking agent experienced longer mechanic
16 ation of deeper sedation after recovery from neuromuscular blocking agent infusion.
17 s (4.6 2.2 d) compared with patients without neuromuscular blocking agent infusions (2.4 2.2 d; p < 0
18 sedation was prolonged in patients receiving neuromuscular blocking agent infusions (4.6 2.2 d) compa
19 resented equivocal evidence on the effect of neuromuscular blocking agent infusions in patients with
20 n completely mediated the negative effect of neuromuscular blocking agent infusions on in-hospital mo
21 per sedation revealed a beneficial effect of neuromuscular blocking agent infusions on mortality (49%
22 eper sedation is a mediator of the effect of neuromuscular blocking agent infusions on mortality.
23 atory distress syndrome patients who receive neuromuscular blocking agent infusions, a prolonged, hig
24 luded, of whom 577 (16.9%) were treated with neuromuscular blocking agent infusions, for a mean (sd)
25    She is placed in the prone position and a neuromuscular blocking agent is administered, without im
26 espiratory infection, early treatment with a neuromuscular blocking agent is associated with lower in
27                                   On day 13, neuromuscular blocking agent therapy was discontinued, b
28 n the propensity for treatment, receipt of a neuromuscular blocking agent was associated with a reduc
29 with a propensity score approach, the use of neuromuscular blocking agent was found to be a significa
30 tients who received a continuous infusion of neuromuscular blocking agent were more likely to be youn
31 ithout spontaneous breathing (prevented by a neuromuscular blocking agent).
32 ered one or more sedative, analgesic, and/or neuromuscular blocking agent, range 1-9 drugs, mean 2.5
33 neuromuscular blockade: encapsulation of the neuromuscular blocking agent, resulting in inactivation.
34 e adult cats, anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificial
35 who did not receive a continuous infusion of neuromuscular blocking agent, with a higher frequency of
36 tanic) contractions in a rat model mimicking neuromuscular blocking agent-induced muscle block used d
37               An analysis using the hospital neuromuscular blocking agent-prescribing rate as an inst
38 nts all had ARDS and had been treated with a neuromuscular blocking agent.
39 s that a protocol should include guidance on neuromuscular-blocking agent administration in patients
40                         1) We suggest that a neuromuscular-blocking agent be administered by continuo
41  practice suggests that a reduced dose of an neuromuscular-blocking agent be used for patients with m
42 sistent weight over another when calculating neuromuscular-blocking agent doses in obese patients.
43  patients receiving a continuous infusion of neuromuscular-blocking agent receive a structured physio
44 cting rather than long-acting intraoperative neuromuscular blocking agents (1 RCT) reduce risk.
45  studied the ability of four nondepolarizing neuromuscular blocking agents (atracurium, gallamine, me
46 guidelines during use of continuous-infusion neuromuscular blocking agents (NMB) in the intensive car
47 perioperative anaphylaxis but not exposed to neuromuscular blocking agents (NMBA) were included.
48                                              Neuromuscular blocking agents (NMBAs) are muscle relaxan
49                    Anaphylactic reactions to neuromuscular blocking agents (NMBAs) can be severe and
50 e administration of analgesic, sedative, and neuromuscular blocking agents (NMBAs) for each patient.
51                                   The use of neuromuscular blocking agents (NMBAs) in pediatric acute
52                                              Neuromuscular blocking agents (NMBAs) induce dose-depend
53                                   Allergy to neuromuscular blocking agents (NMBAs) is the most import
54           The use of sedatives, opioids, and neuromuscular blocking agents (NMBAs) may delay weaning
55 ith a major adverse event whereas the use of neuromuscular blocking agents (NMBAs) was associated wit
56  (EELI) increase after the administration of neuromuscular blocking agents (NMBAs), clinical factors
57  postulated cause of allergic anaphylaxis to neuromuscular blocking agents (NMBAs).
58 o significantly more likely to have received neuromuscular blocking agents (p = .004) or propofol (p
59                 Without their use, dosing of neuromuscular blocking agents and anticholinesterases is
60     Long-term treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the
61          We examined the association between neuromuscular blocking agents and ICU-acquired weakness,
62 o assess the relationship between the use of neuromuscular blocking agents and in-hospital mortality.
63                     The relationship between neuromuscular blocking agents and neuromuscular dysfunct
64 alysis suggests a modest association between neuromuscular blocking agents and neuromuscular dysfunct
65 ed trial did not show an association between neuromuscular blocking agents and neuromuscular dysfunct
66 ndromes were also associated with the use of neuromuscular blocking agents and prolonged mechanical v
67 f an adverse relationship between the use of neuromuscular blocking agents and skeletal muscle weakne
68                                              Neuromuscular blocking agents are commonly used in criti
69                                              Neuromuscular blocking agents are routinely used in the
70 d guidelines and protocols could ensure that neuromuscular blocking agents are used and monitored app
71                                              Neuromuscular blocking agents are used commonly to induc
72 y of muscle function after surgery involving neuromuscular blocking agents can be monitored and, in a
73 ardiac diagnosis among patients who received neuromuscular blocking agents compared with other diagno
74                              However, use of neuromuscular blocking agents during emergent airway man
75 om retrospective studies suggest that use of neuromuscular blocking agents during general anaesthesia
76                             Intensivists use neuromuscular blocking agents for a variety of clinical
77 tion for pain and agitation, 5) sedation and neuromuscular blocking agents for increased work of brea
78 s, 'experts' in the clinical pharmacology of neuromuscular blocking agents have advocated routine int
79 o describe the use of continuous infusion of neuromuscular blocking agents in mechanically ventilated
80                     The use of sedatives and neuromuscular blocking agents in the ICU is positively a
81               This includes the injection of neuromuscular blocking agents into anterior scalene musc
82              We hypothesized that the use of neuromuscular blocking agents is associated with a decre
83 therefore aimed to assess whether the use of neuromuscular blocking agents is associated with postope
84    Recent trials suggest that treatment with neuromuscular blocking agents may improve survival in pa
85 nsible for ICU-AW and provides evidence that neuromuscular blocking agents may not be a major cause o
86 suggested that some pairs of nondepolarizing neuromuscular blocking agents might be more efficacious
87 er that irrespective of chemical structural, neuromuscular blocking agents might produce prolonged pa
88 ted Cox regression analysis found the use of neuromuscular blocking agents to be a significant predic
89 his system have the capability to administer neuromuscular blocking agents to facilitate intubation (
90 uscular disease, addiction, epilepsy and for neuromuscular blocking agents used during surgery.
91 ted data included demographics, sedation and neuromuscular blocking agents used, mechanical ventilati
92                                   The use of neuromuscular blocking agents was associated with a lowe
93                                   The use of neuromuscular blocking agents was associated with an inc
94                                       Use of neuromuscular blocking agents was associated with signif
95 nd route of administration for sedatives and neuromuscular blocking agents were abstracted from ICU f
96                        Patients who received neuromuscular blocking agents were younger (mean age, 62
97                  Total body weight dosing of neuromuscular blocking agents will result in a prolonged
98 ompare the outcomes of patients treated with neuromuscular blocking agents within the first 2 hospita
99 ing trials, lung-protective ventilation, and neuromuscular blocking agents).
100 ovenous extracorporeal membrane oxygenation, neuromuscular blocking agents, and positive end-expirato
101 romuscular weakness and included charges for neuromuscular blocking agents, continuous mechanical ven
102 n performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhe
103  predominant one, along with potentiation by neuromuscular blocking agents, immobilization, and proba
104 modynamic monitoring and use of sedative and neuromuscular blocking agents, more mechanical ventilati
105 requirements for vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients th
106 groups bind tightly to several commonly used neuromuscular blocking agents, such as rocuronium, in aq
107                                   The use of neuromuscular blocking agents, when used by intensivists
108 ically ventilated children in PICUs received neuromuscular blocking agents.
109 ery of neuromuscular function induced by any neuromuscular blocking agents.
110 d for a safe drug to antagonize all types of neuromuscular blocking agents.
111 he adverse events associated with the use of neuromuscular blocking agents.
112 piratory profiles were anaesthetised without neuromuscular blocking agents.
113 ght complexes in a 1: 1 ratio with steroidal neuromuscular blocking agents.
114 al, many monitors are affected by the use of neuromuscular blocking agents.
115 igned that selectively encapsulate steroidal neuromuscular blocking agents.
116 ects of combining different non-depolarizing neuromuscular blocking agents.
117 eroids in combination with variable doses of neuromuscular blocking agents.
118 ined after discontinuation of treatment with neuromuscular blocking agents.
119 prescriptions of sedative, analgesic, and/or neuromuscular blocking agents; nurse administration of t
120                          10) We suggest that neuromuscular-blocking agents be discontinued at the end
121   6) Optimal clinical practice suggests that neuromuscular-blocking agents be discontinued prior to t
122 ht or adjusted body weight) when calculating neuromuscular-blocking agents doses for obese patients.
123 make no recommendation on the routine use of neuromuscular-blocking agents for patients undergoing th
124                   3) We suggest a trial of a neuromuscular-blocking agents in life-threatening situat
125   8) We make no recommendation on the use of neuromuscular-blocking agents in pregnant patients.
126                           4) We suggest that neuromuscular-blocking agents may be used to manage over
127 est against the routine administration of an neuromuscular-blocking agents to mechanically ventilated
128 in patients with myasthenia gravis receiving neuromuscular-blocking agents.
129 r patients receiving continuous infusions of neuromuscular-blocking agents.
130  unintended extubation in patients receiving neuromuscular-blocking agents.
131 in patients receiving continuous infusion of neuromuscular-blocking agents.
132  specific to patients receiving infusions of neuromuscular-blocking agents.
133 sedation during continuous administration of neuromuscular-blocking agents.
134 of less than 180 mg/dL in patients receiving neuromuscular-blocking agents.
135  stimulators allows clinicians to administer neuromuscular blocking and reversal agents in a rational
136 itatively by acceleromyography, and residual neuromuscular block be reversed.
137 gitation behaviors; sedative, analgesic, and neuromuscular blocking drug administration; ventilation
138 istically associated with bronchospasm was a neuromuscular blocking drug, with both IgE- or non-IgE-m
139                             Sugammadex binds neuromuscular blocking drugs and encapsulates them, maki
140 gammadex is a novel drug that binds selected neuromuscular blocking drugs and prevents them from acti
141                    We showed that the use of neuromuscular blocking drugs in general anaesthesia is a
142                                              Neuromuscular blocking drugs were introduced into clinic
143 potent reversal agent for rocuronium-induced neuromuscular block in rats.
144 t pulmonary function, and even mild residual neuromuscular block increases the risk of severe postope
145                                     Residual neuromuscular block is a relatively frequent occurrence
146 l studies demonstrating complement-dependent neuromuscular block may be relevant to the clinical path

 
Page Top